Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Oregon Health and Science University | Genentech | Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 05, 2021
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Oregon Health and Science University | Genentech | Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
SPARK-ALL: Calaspargase Pegol in Adults with ALL
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 26, 2021
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 13, 2017
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : EsPhALL | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 02, 2017
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : EsPhALL | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 23, 2016
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Leadiant Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 17, 2013
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Leadiant Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable